Why Do Physicians Switch From One Antipsychotic Agent to Another?: The "Physician Drug Stereotype"

Abstract: There is a lack of research on why physicians select a certain drug in an individual case and not another available alternative, although this drug selection process is important for quality assurance and cost control. Four hundred ninety-five psychiatrists documented in a standardized form patient and illness characteristics of 1711 schizophrenic outpatients who were switched for individual clinical reasons from an ongoing neuroleptic treatment to olanzapine, and of another 1654 schizophrenic outpatients whose present neuroleptic medication was continued. Physicians also filled in the "Reason for Treatment Selection Questionnaire." Patients who were switched to olanzapine were more ill and showed more preexisting extrapyramidal symptoms and less patient compliance. Reasons of psychiatrists to switch to olanzapine were the expectation of better efficacy and tolerability of the present treatment and patient preferences to continue with the present medication. The price of olanzapine is seen as a reason not to select olanzapine but has no effect on the treatment decision. The "physician drug stereotype" of olanzapine corresponds with clinical data on the efficacy and tolerability of olanzapine. The data show that medical decisions about drug selection are multidimensional, integrating knowledge about the clinical properties of the drug, personal experiences and information about the individual case. The Reason for Treatment Selection Questionnaire is an instrument that allows to objectively assess important aspects of medical decision making, to generate psychological drug profile, and to understand why physicians prefer one drug over alternatives.

[1]  M Linden,et al.  Therapeutic Standards in Psychopharmacology and Medical Decision-Making , 1994, Pharmacopsychiatry.

[2]  R. Tamura,et al.  Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol , 1999, British Journal of Psychiatry.

[3]  R. Dardennes,et al.  Olanzapine for schizophrenia. , 2005, The Cochrane database of systematic reviews.

[4]  Ronald R. Brown,et al.  Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine , 2005, International clinical psychopharmacology.

[5]  G. Tollefson,et al.  Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol , 1998, European Neuropsychopharmacology.

[6]  G. Tollefson,et al.  Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial , 1996, Psychopharmacology.

[7]  R. Tandon,et al.  Efficacy of newer generation antipsychotics in the treatment of schizophrenia , 2003, Psychoneuroendocrinology.

[8]  C. Beasley,et al.  Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial , 1997, European Neuropsychopharmacology.

[9]  J. Ishigooka,et al.  Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: Results of an open‐label multicenter study in Japan , 2001, Psychiatry and clinical neurosciences.

[10]  J. Lieberman,et al.  Olanzapine versus haloperidol in the treatment of first episode psychosis , 1998, Schizophrenia Research.

[11]  G. Tollefson,et al.  Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. , 1996, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[12]  G. Tollefson,et al.  Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses , 1998, British Journal of Psychiatry.

[13]  R. Tamura,et al.  Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.

[14]  J. Calabrese,et al.  Olanzapine Versus Placebo in Acute Mania: Treatment Responses in Subgroups , 2003, Journal of clinical psychopharmacology.

[15]  G. Chapman,et al.  Are More Options Always Better? , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  D. Kupfer,et al.  Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. , 2002, Archives of general psychiatry.

[17]  G. Tollefson,et al.  Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. , 1997, Psychiatric services.

[18]  G. Tollefson,et al.  Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. , 1997, The Journal of clinical psychiatry.

[19]  S. Montgomery,et al.  First clinical experience with olanzapine (LY 170053): results of an open‐label safety and dose‐ranging study in patients with schizophrenia , 1995, International clinical psychopharmacology.

[20]  J. Peuskens Clinical effectiveness in adults with chronic schizophrenia , 2004, European Neuropsychopharmacology.

[21]  Philip Seeman,et al.  Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.

[22]  M. Tohen,et al.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. , 2000, Archives of general psychiatry.

[23]  L. Yatham Efficacy of Atypical Antipsychotics in Mood Disorders , 2003, Journal of clinical psychopharmacology.

[24]  G. Tollefson,et al.  The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations , 1997, Schizophrenia Research.

[25]  A. Cools,et al.  The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine , 1995, Psychopharmacology.

[26]  M. Linden,et al.  Therapist individuality in the diagnosis and treatment of depression. , 1993, Journal of affective disorders.

[27]  Vimla L. Patel,et al.  Emerging paradigms of cognition in medical decision-making , 2002, J. Biomed. Informatics.

[28]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[29]  A. Fasoli [Clinical decision analysis]. , 1986, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

[30]  A. Altamura,et al.  Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. , 2004, Journal of clinical psychopharmacology.

[31]  G. Tollefson,et al.  A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse , 2003, Journal of clinical psychopharmacology.

[32]  G. Tollefson,et al.  Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. , 1997, American Journal of Psychiatry.

[33]  G. Tollefson,et al.  Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. , 1997 .

[34]  M. Linden The role of the patient in treatment decisions. , 1997, Modern problems of pharmacopsychiatry.